Quirem Medical develops and commercializes radioactive microspheres based on Holmium-166 for Selective Internal Radiation Therapy (SIRT). Holmium-166 microspheres can be visualized and quantified to facilitate patient selection, therapy planning and treatment verification. Through our innovative Holmium-166 platform technology, we aim to empower physicians to further drive treatment outcome of unresectable liver cancer after SIRT in four simple steps:
Deventer, June 15, 2021 – A first clinical QuiremSpheres® patient procedure took place with radioactive holmium-166 microspheres that were activated at the BR2 reactor in
28 January 2021 – NIJMEGEN – Today Her Majesty the Queen Máxima paid a virtual working visit to the RadboudUMC. During the visit, she focused
09/12/2020 – LEUVEN, BELGIUM Quirem Medical, a Terumo company, is awarded top 3 innovative medical device in the 2019 Belgian Galenus prize with the innovative
20 OCTOBER 2020, DEVENTER – Today a first clinical QuiremSpheres® patient procedure took place with a patient dose prepared using a novel hotlab manufacturing process
TOKYO and DEVENTER, Netherlands, July 15, 2020 — Terumo Corporation (TSE: 4543) today announced it has completed the acquisition of Quirem Medical B.V., a Netherlands-based healthcare startup specializing in
DEVENTER, Jun. 8 2020 – Quirem Medical announced today it received CE-mark approval for the latest version of Q-Suite®, dosimetry software for holmium-166 SIRT. Q-Suite®
Terumo Europe N.V. and Quirem Medical B.V are proud to share the latest key publication regarding holmium-166 (QuiremSpheres®) Selective Internal Radiation Therapy (SIRT). On 27
Radiology of the Future revolves around smart and fast image processing. Achieving this requires research and entrepreneurship. This is the reason that Thirona, Quirem, and
29 January 2020 – LEIPZIG On Wednesday 29th of January 2020 a QuiremSpheres® live case was performed to treat a patient suffering from intrahepatic cholangiocellular
Quirem Medical is pleased to share that yet another Holmium-166 (QuiremSpheres®) related scientific article has been published, after recently having reported on the publication of
Telephone: +31 85 0404170
E-mail: info.quirem@terumo-europe.com